

National Cancer Institute  
Institutional Review Board  
**AGENDA (\*revised 10/2/14)**  
**October 6, 2014**  
1:00 – 5:00 pm  
CRC 10/3-1608

1. **Review of Draft Minutes, September 22, 2014**
2. **Announcements**
3. **Old Business**
4. **New Business**
5. **Problem Report Forms**
6. **Other Expedited Actions**
7. **Continuing Reviews**
8. **\*Amendment**      14C0157A, "Phase 1 Study of Ibrutinib and Immuno-chemotherapy using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma"—Kieron Dunleavy, PI
9. **Initial Review**      P121087, "Prospective Procurement of Urothelial Cancer Tissue to Identify the Molecular and Genetic Basis of Bladder Cancer" - Piyush Agarwal, PI
10. **Initial Review**      P141705, "Phase 2 Study of MK-3475 in Patients with Microsatellite Unstable (MSI) Tumors" - Tim Greten, PI
11. **Initial Review**      P141598, "Biomarkers in Acute Graft-Versus-Host Disease (GVHD) and Extracorporeal Photopheresis added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD" - David Halverson, PI
12. **Initial Review**      P131448, "A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation" - Steven Pavletic, PI